News articles about NuVasive (NASDAQ:NUVA) have been trending somewhat positive recently, according to AlphaOne. The research firm, a subsidiary of Accern, scores the sentiment of news coverage by analyzing more than twenty million blog and news sources in real time. AlphaOne ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. NuVasive earned a news sentiment score of 0.15 on AlphaOne’s scale. AlphaOne also assigned news headlines about the medical device company an impact score of 81 out of 100, indicating that recent news coverage is very likely to have an impact on the stock’s share price in the next few days.
These are some of the media headlines that may have impacted AlphaOne Sentiment’s scoring:
- Regenerative Medicine Market to increase at a CAGR of 11.1% during the forecast period from 2015 to 2019 (mynewsdesk.com)
- Shares Seesawing on Volume: NuVasive Inc (NUVA) – Financial News Review (finnewsreview.com)
- NuVasive, Inc. (NUVA) analyst mean recommendation for this stock stands at 1.90 – Stocks Gallery (stocksgallery.com)
- Orthopedic Implants Market Research Findings, Market Growth Factors Analysis and Forecasts (2017-2025) (medgadget.com)
- Spine Surgery Devices Market 2017 Analysis, Size, Share, Growth, Segment, Trends and Forecast 2021 (medgadget.com)
NuVasive (NASDAQ:NUVA) last announced its quarterly earnings data on Tuesday, April 25th. The medical device company reported $0.38 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.37 by $0.01. The business had revenue of $249.86 million during the quarter, compared to analyst estimates of $250.52 million. NuVasive had a return on equity of 12.63% and a net margin of 5.35%. The company’s revenue was up 16.2% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.34 earnings per share.
Several equities research analysts recently weighed in on the company. Cowen and Company reaffirmed an “outperform” rating and set a $85.00 price target on shares of NuVasive in a report on Monday, May 15th. TheStreet raised NuVasive from a “c+” rating to a “b” rating in a report on Wednesday, May 3rd. Royal Bank Of Canada increased their price target on NuVasive from $76.00 to $85.00 and gave the stock an “outperform” rating in a report on Tuesday, June 6th. Piper Jaffray Companies increased their price target on NuVasive from $80.00 to $90.00 and gave the stock an “overweight” rating in a report on Monday, June 12th. Finally, Barclays PLC increased their price target on NuVasive from $80.00 to $82.00 and gave the stock an “overweight” rating in a report on Monday, April 24th. Two investment analysts have rated the stock with a hold rating and ten have given a buy rating to the company. The stock currently has a consensus rating of “Buy” and an average target price of $79.82.
ILLEGAL ACTIVITY WARNING: “NuVasive (NUVA) Receiving Somewhat Positive Press Coverage, Study Finds” was originally posted by BBNS and is owned by of BBNS. If you are accessing this story on another domain, it was stolen and republished in violation of international copyright and trademark legislation. The legal version of this story can be viewed at https://baseballnewssource.com/markets/nuvasive-nuva-receiving-somewhat-positive-press-coverage-study-finds/1043895.html.
Nuvasive, Inc is a medical device company. The Company focuses on developing minimally-disruptive surgical products and procedurally-integrated solutions for the spine surgery. Its product portfolio focuses on applications for spine fusion surgery, including biologics used to aid in the spinal fusion process.
Receive News & Ratings for NuVasive Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NuVasive Inc. and related companies with our FREE daily email newsletter.